Among 53 AE cases, 19 had serum or CSF antibodies. Among antibody-positive AE patients, there were 9 (47%) males and 10 (53%) females; 10 (52.6%) anti-NMDAR-antibodies, 5 (26%) anti-VGKC-antibodies and 4 (21%) GAD65-antibodies. Clinical presentation included neuropsychiatric symptoms (68.4%), altered mental status (63%), movement disorders (57.9%), new-onset seizures (52.6%), speech difficulties (15.7%), status epilepticus (10.5%) and sleep dysfunction (5%). One patient with anti-LGI1 VGKC-antibodies had faciobrachial dystonic seizures. 2 (10.5%) required ICU admission and 9 (47.3%) experienced relapses needing readmissions. MRI Brain was abnormal with T2 hyperintensities in 13 patients (31.5%) - 3 in parietal lobe, 2 in temporal lobe and 2 in frontal lobe. 7 (36.8%) had focal EEG findings. 9(47.3%) had CSF pleocytosis and protein was normal in all patients. Acute management consisted of several different combination regimens including intravenous steroids (89%), intravenous immunoglobulin (IVIG) (84%), rituximab (15.8%) and plasma exchange (PLEX) (10.5%). Maintenance regimen included IVIG (42%), Rituximab (36.8%) and 1 PLEX. 6 (31.5%) attained complete remission; 1 underwent excision of ovarian teratoma. Long term sequalae included neurocognitive disturbances (52.6%), epilepsy (31.5%) and movement disorders (5%).